Strategic partnerships PHAR actively engages with large pharma partners (e.g., Bristol Myers Squibb, Genentech) on treatment patterns, resource utilization, and cost analyses. This indicates a receptiveness to collaboration on real-world evidence, health economics, and payer-focused studies that can open joint-project opportunities.

Health economics focus The company’s work with PhRMA on post-approval R&D impacts and cost-effectiveness discussions signals potential for expanding health economics and outcomes research services, including HTA support, cost-effectiveness modeling, and reimbursement strategy consulting.

Clinical data capabilities PHAR demonstrates experience with claims-based methodologies and disease-specific patient identification (e.g., NMOSD) through collaborations and presentations, suggesting an opportunity to offer advanced analytics, real-world data studies, and observational research services.

Scale and reach With a mid-market revenue range and partnerships across multiple large organizations, PHAR represents a viable partner for scalable consulting programs, multi-site studies, and ongoing advisory engagements that can be leveraged across a broad life sciences client base.

Digital and tech readiness Utilizing platforms like WordPress, Shopify, and standard security headers, PHAR shows a modern digital presence. There is potential to upsell in data-driven marketing analytics, client portals, and enhanced outcome reporting tools for clients.